Lupin gains tentative FDA approval for Empagliflozin, Linagliptin, Metformin Hydrochloride ER tablets Read more
Zydus receives final approval from US FDA for Empagliflozin and Metformin Hydrochloride Tablets Read more
Empagliflozin reduces hospitalisation risk for heart-failure and cardiovascular death by 21 per cent, shows Boehringer Ingelheim’s Emperor-Preserved trial Read more
SGLT-2 inhibitors may primarily drive growth of branded heart failure treatment market: GlobalData Read more
Empagliflozin reduced risk of death and hospitalisation for heart failure by 25 per cent in adults Read more
Alembic Pharmaceuticals receives US FDA’s tentative approval for Empagliflozin and Metformin Hydrochloride Tablets Read more